Wuhan Hiteck Biological Pharma Co (300683) Fair Value & Analysis
Healthcare · CN · Market cap 3.3B CNY
Fair value as of: Jul 9, 2026
From 1 valuation models · updated today
Fair value updated Jul 9, 2026 — revised from ¥74.28 to ¥6.22 (−91.6%) since Jun 24, 2026. Share price +0.1% over the past month.
Price vs Fair Value (12 months)
12‑month range ¥23.33 – ¥59.56 · fair‑value band ¥4.10 – ¥7.77 · the ¥25.90 price screens above the ¥6.22 fair value. As of Jul 9, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Wuhan Hiteck Biological Pharma Co (300683) currently trades at ¥25.90, while our model-based Fair Value estimate is ¥6.22 — implying the stock looks roughly 76.0% overvalued today. We read business quality at 39/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, Wuhan Hiteck Biological Pharma Co generated revenue of 544M CNY at a net margin of -44.2%. Revenue grew 1.5% year over year. It earns a return on equity of -10.8%. The balance sheet holds a net cash position of 395M CNY. Fundamentals as of Jul 9, 2026
Our scenario range runs from ¥4.10 (bear case) to ¥7.77 (bull case); at ¥25.90, the current price sits above that range. The share trades about 58% below its 52-week high and 9% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside — at -76%, 300683 screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 9, 2026. TTM = trailing twelve months.
About the company
Wuhan Hiteck Biological Pharma Co.,Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of bio engineering products and freeze-dried powder injection in China. Its products include Epramine for injection; mouse nerve growth factor for injection; Anewway, a mouse nerve growth factor for injection; omeprazole sodium for injection, an alternative therapy for duodenal ulcer, gastric ulcer, reflux esophagitis, and Zollinger-Ellison syndrome; adenosine cyclophosphate for injection that is used for angina pectoris, myocardial infarction, myocarditis, and cardiogenic shock; aciclovir dispersible tablets for the treatment of genital herpes virus infection, herpes zoster, and immune deficiency chickenpox; Pentoxone theobromine injection; Roxatidine Acetate Hydrochloride for Injection; and Terizazole phosphate for injection. The company also provides measles and rubella virus nucleic acid detection kits; isolation and identification tubes and kits …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Wuhan Hiteck Biological Pharma Co reported revenue of ¥541M in FY2025 versus ¥615M in FY2021, a compound −3.1%/yr. Reported net income was −¥231M in FY2025.
Is 300683 fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 9, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$26.19 | R$26.01 | -1% |
| Hansoh Pharmaceutical Group 3692 | HK$29.32 | HK$23.94 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,788 | ₹2,035 | -70% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,421 | ₹1,504 | -66% |
| Cipla Limited CIPLA | ₹1,401 | ₹592.37 | -58% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,098 | ₹507.31 | -54% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,272 | ₹720.15 | -43% |
| PharmaEssentia Corporation 6446 | 937.00 TWD | 322.35 TWD | -66% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Wuhan Hiteck Biological Pharma Co (300683) undervalued?
What is the fair value of 300683?
What is the quality score of 300683?
What is the revenue of Wuhan Hiteck Biological Pharma Co (300683)?
What is the net profit margin of 300683?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.